Related references
Note: Only part of the references are listed.RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Ryan M. Carr et al.
NATURE COMMUNICATIONS (2021)
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells
Haifang Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Epstein-Barr virus-encoded LMP 1 regulated Pim 1 kinase expression promotes nasopharyngeal carcinoma cells proliferation
Ran-ran Ding et al.
ONCOTARGETS AND THERAPY (2019)
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Zhimin Gu et al.
CANCER DISCOVERY (2019)
Subtype-specific regulatory network rewiring in acute myeloid leukemia
Salam A. Assi et al.
NATURE GENETICS (2019)
Rewiring of the Transcription Factor Network in Acute Myeloid Leukemia
Salam A. Assi et al.
CANCER INFORMATICS (2019)
Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias
Ashwin Sridharan et al.
BLOOD ADVANCES (2019)
A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies
Daichi Inoue et al.
LEUKEMIA (2018)
Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy
Peng Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Chiara Elena et al.
BLOOD (2016)
Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels
Daichi Inoue et al.
EXPERIMENTAL HEMATOLOGY (2016)
The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent
G. Kong et al.
LEUKEMIA (2016)
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado et al.
NATURE (2016)
Kras is Required for Adult Hematopoiesis
Alisa Damnernsawad et al.
STEM CELLS (2016)
Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma
Deepanwita Sengupta et al.
EPIGENETICS (2015)
Loss of Dnmt3a and endogenous KrasG12D+ cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis
Y-I Chang et al.
LEUKEMIA (2015)
Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice
Jiapeng Wang et al.
BLOOD (2014)
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
M. M. Patnaik et al.
LEUKEMIA (2014)
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome
T-C Chen et al.
BLOOD CANCER JOURNAL (2014)
NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions
Jinyong Wang et al.
BLOOD (2013)
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Raphael Itzykson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
Omar Abdel-Wahab et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals
J. Du et al.
LEUKEMIA (2013)
The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics
O. Abdel-Wahab et al.
LEUKEMIA (2013)
Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness
Qing Li et al.
NATURE (2013)
Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in Nras-Driven Hematopoietic Transformation
Jin Xu et al.
CANCER DISCOVERY (2013)
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
Britta Will et al.
BLOOD (2012)
ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Omar Abdel-Wahab et al.
CANCER CELL (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
Anwesha Dey et al.
SCIENCE (2012)
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus
Qing Li et al.
BLOOD (2011)
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner
Jinyong Wang et al.
BLOOD (2011)
Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia
Jinyong Wang et al.
BLOOD (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Share Paper
